16:20:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning MNTC 0.00 SEK
2024-05-23 Årsstämma
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-12 X-dag ordinarie utdelning MNTC 0.00 SEK
2023-05-11 Årsstämma
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-03 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 X-dag ordinarie utdelning MNTC 0.00 SEK
2022-04-27 Årsstämma
2022-02-03 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-05-07 X-dag ordinarie utdelning MNTC 0.00 SEK
2021-05-06 Årsstämma
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-28 X-dag ordinarie utdelning MNTC 0.00 SEK
2020-05-27 Årsstämma
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-08-28 Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
2023-08-15 11:20:00

Mentice, a healthcare technology company, proudly announces the latest release of Ankyras in the EU. This clinical decision support application has been designed to support interventional neuroradiologists in selecting the most optimal flow diverters for treating intracranial aneurysms. The updated version of Ankyras offers an intuitive and secure solution for planning, storing, and sharing clinical treatment plans online, offline, and on mobile platforms.

Ankyras is now conveniently accessed through web browsers and compatible iOS and Android apps, facilitating smooth communication and case discussion between physicians and device manufacturers. This feature streamlines and supports clinical procedures, making them more efficient and safe. In situations without internet access, Ankyras provides healthcare professionals with an offline mode, enabling them to stay connected, and integrates seamlessly with the online platform through a unified login system. 

With the latest version of Ankyras, users can now access a broader range of improved functionalities for investigating various device and treatment options in greater detail. Ankyras offers a morphological assessment that provides users with a comprehensive analysis of all artery segments, ensuring they are better equipped to handle real-life challenges. The platform also allows users to telescope multiple flow diverters, evaluate local expansion and porosity, and precisely align the centerline to create the most accurate simulation for a specific device. 

According to Héctor Fernández, Director of Ankyras Development at Mentice, "The use of medical imaging tools for clinical decision-making in intervention is on a rapid growth trajectory – especially with the recent advances in AI-based methods. The launch of Ankyras online is, therefore, very opportune, as it can be utilized as a data collection tool for future software development using AI methods. This latest version will offer customers exemplary guidance on the appropriate flow diverter size and how to position it accurately. Furthermore, it guarantees that the results are futureproofed and ready for more advanced analysis with increasing numbers of treated patients." Moving forward, Mentice plans to expand the Ankyras solution rapidly. This includes securing market clearance in new geographies, seamless integration with other Mentice and strategic partner products, and acquiring new business and accounts in Mentice's core markets.

To keep up with the latest developments in Ankyras and its involvement in device development and treatment strategies for Intracranial Aneurysms, visit www.mentice.com/ankyras. Alternatively, you can visit Mentice's booth #16 during the 15th Annual ESMINT Congress. Our team will be present, showcasing some exciting new developments. If you want a closer look, click here to pre-book your personalized 1-on-1 demo session with us. Trust us, this is an opportunity you don't want to miss!

For more information, please contact:
Renan Cancissu, Director Precision Medicine, Mentice
E-post: ankyras@mentice.com
Mobile: +34 637 892 019


Disclaimer & Regulatory Information
Ankyras is manufactured by Mentice Spain S.L.
Ankyras must be used by trained medical professionals or technicians who are qualified to perform clinical analyses.
 
Mentice subsidiaries and partners will distribute the medical software products developed and manufactured by Mentice Spain S.L. in approved markets.



About Mentice
Mentice (STO: MNTC) is the world leader in proficiency-based simulation solutions for image-guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com